Abstract:Introduction: Hypoxic persistent pulmonary hypertension in the newborn (PPHN) is usually treated with oxygen and inhaled nitric oxide (NO), both pulmonary arterial relaxants. But treatment failure with NO occurs in 25% of cases. We previously demonstrated that 72 h exposure to hypoxia, modeling PPHN, sensitized pulmonary artery smooth muscle cells (PASMC) to the contractile agonist thromboxane and inhibited relaxant adenylyl cyclase (AC) activity. Methods: In this study, we examined the effects of sodium nitroprusside (SNP), as NO donor, on the thromboxane-mediated contraction and NO-independent relaxation pathways and on reactive oxygen species (ROS) accumulation in PASMC. In addition, we examined the effect of the peroxynitrite scavenger 5,10,15,20-Tetrakis (4-sulfonatophenyl)porphyrinato Iron (III) (FeTPPS) on these processes. Results: Exposure of PASMC to 72 h hypoxia increased total intracellular ROS compared to normoxic control cells and this was mitigated by treatment of cells with either SNP or FeTPPS. Total protein nitrosylation was increased in hypoxic PASMC compared to controls. Both normoxic and hypoxic cells treated with SNP exhibited increased total protein nitrosylation and intracellular nitrite; this was reduced by treatment with FeTPPS. While cell viability and mitochondrial number were unchanged by hypoxia, mitochondrial activity was decreased compared to controls; addition of FeTPPS did not alter this. Basal and maximal mitochondrial metabolism and ATP turnover were reduced in hypoxic PASMC compared to controls. Hypoxic PASMC had higher basal Ca2+, and a heightened peak Ca2+ response to thromboxane challenge compared to controls. Addition of SNP further elevated the peak Ca2+ response, while addition of FeTPPS brought peak Ca2+ response down to control levels. AC mediated relaxation was impaired in hypoxic PASMC compared to controls but was normalized following treatment with FeTPPS. Addition of SNP inhibited adenylyl cyclase activity in both normoxic and hypoxic PASMC. Moreover, addition of the Ca2+ chelator BAPTA improved AC activity, but the effect was minimal. Discussion: We conclude that NO independently augments contraction and inhibits relaxation pathways in hypoxic PASMC, in part by a mechanism involving nitrogen radical formation and protein nitrosylation. These observations may partially explain impaired effectiveness of NO when treating hypoxic pulmonary hypertension.

Pulmonary hypertension and oxidative stress: Where is the link?

Optimal oxygenation and role of free radicals in PPHN

Hyperoxia-induced Changes in Estradiol Metabolism in Postnatal Airway Smooth Muscle

Oxidative stress in patients with pulmonary hypertension

Oxidative Stress and Antioxidant Therapy in Pulmonary Hypertension

Maternal Omega-3 PUFA Supplementation Prevents Hyperoxia-Induced Pulmonary Hypertension in the Offspring

Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension

Nitric oxide and beyond: new insights and therapies for pulmonary hypertension

Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates

Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension

Oxidative Stress and Neonatal Respiratory Extracorporeal Membrane Oxygenation

Redox Regulation of Ion Channels and Receptors in Pulmonary Hypertension

Nitric oxide augments signaling for contraction in hypoxic pulmonary arterial smooth muscle—Implications for hypoxic pulmonary hypertension

Oxidative Stress and Vascular Remodeling in Pulmonary Hypertension

How Do We Monitor Oxygenation during the Management of PPHN? Alveolar, Arterial, Mixed Venous Oxygen Tension or Peripheral Saturation?

Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn

How Do We Monitor Oxygenation During The Management of PPHN? Alveolar, Arterial or Mixed Oxygen Tension or Peripheral Saturation?

The Fetus Can Teach Us: Oxygen and the Pulmonary Vasculature

Advances in Neonatal Pulmonary Hypertension

A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension.

Oxidative Stress, Kinase Activation, and Inflammatory Pathways Involved in Effects on Smooth Muscle Cells During Pulmonary Artery Hypertension Under Hypobaric Hypoxia Exposure